Acute Promyelocytic Leukemia
Symptoms, Doctors, Treatments, Advances & More

Acute Promyelocytic Leukemia Overview

Save information for later
Sign Up

Learn About Acute Promyelocytic Leukemia

View Main Condition: Leukemia

What is the definition of Acute Promyelocytic Leukemia?
Acute promyelocytic leukemia (APL) is an aggressive type of acute myeloid leukemia in which there are too many immature blood-forming cells (promyelocytes) in the blood and bone marrow. This build up of promyelocytes leads to a shortage of normal white and red blood cells and platelets in the body. The signs and symptoms of APL include an increased risk to both bleed and form blood clots. Individuals may also experience excessive tiredness, pain in affected areas, loss of appetite, and weight loss. It is caused by a genetic change that is acquired over a person's lifetime, usually involving a translocation between chromosomes 15 and 17.
What are the alternative names for Acute Promyelocytic Leukemia?
  • Acute promyelocytic leukemia
  • AML M3
  • AML with t(15;17)(q22;q12);(PML/RARalpha) and variants
  • APML
  • Acute myeloblastic leukemia 3
  • Acute myeloblastic leukemia type 3
  • Acute myeloid leukemia with t(15;17)(q22;q12);(PML/RARalpha) and variants
Who are the top Acute Promyelocytic Leukemia Local Doctors?
Richard M. Stone
Elite in Acute Promyelocytic Leukemia
Dr. Richard M. Stone
Hematology Oncology | Hematology | Oncology
Elite in Acute Promyelocytic Leukemia
Dr. Richard M. Stone
Hematology Oncology | Hematology | Oncology

Dana-Farber Cancer Institute, Adult Leukemia Program

450 Brookline Avenue, 
Boston, MA 
617-632-2214
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Richard Stone is a Hematologist Oncology specialist and a Hematologist in Boston, Massachusetts. Dr. Stone is rated as an Elite provider by MediFind in the treatment of Acute Promyelocytic Leukemia. His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Bone Marrow Transplant.

Elite in Acute Promyelocytic Leukemia
Dr. Jessica K. Altman
Hematology | Oncology
Elite in Acute Promyelocytic Leukemia
Dr. Jessica K. Altman
Hematology | Oncology
675 N St Clair St Ste 21-100, Galter Pavilion, 
Chicago, IL 
866-587-4322
Experience:
25+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jessica Altman is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Altman has been practicing medicine for over 25 years and is rated as an Elite provider by MediFind in the treatment of Acute Promyelocytic Leukemia. Her top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Acute Promyelocytic Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

 
 
 
 
Learn about our expert tiers
Learn More
Hagop Kantarjian
Elite in Acute Promyelocytic Leukemia
Dr. Hagop Kantarjian
Oncology
Elite in Acute Promyelocytic Leukemia
Dr. Hagop Kantarjian
Oncology

Office

1400 Holcombe Blvd Unit 428, 
Houston, TX 
713-792-2813
Languages Spoken:
English
See accepted insurances

Hagop Kantarjian is an Oncologist in Houston, Texas. Dr. Kantarjian is rated as an Elite provider by MediFind in the treatment of Acute Promyelocytic Leukemia. His top areas of expertise are Chronic Myelogenous Leukemia (CML), Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Bone Marrow Transplant, and Bone Marrow Aspiration.

View All Doctors
What are the latest Acute Promyelocytic Leukemia Clinical Trials?
Phase I Trial of TURALIO (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor (TGCT)
Phase I Trial of TURALIO (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor (TGCT)
Who is this study for: Child to adult patients with Recurrent or Refractory Solid Tumors or Acute Leukemia
Enrollment Status: Recruiting
Publish Date: December 31, 2025
Intervention Type: Drug
Study Drug: PLX3397
Study Phase: Phase 1

Background: \- Some people with cancer have solid tumors. Others have refractory leukemia. This may not go away after treatment. Researchers want to see if a drug called TURALIO(R) can shrink tumors or stop them from growing.

Match to trials
Find the right clinical trials for you in under a minute
Get started
Phase II Study of Treatment of Acute Promyelocytic Leukemia (APL) With ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin (GO)
Phase II Study of Treatment of Acute Promyelocytic Leukemia (APL) With ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin (GO)
Who is this study for: Child to adult patients with Acute Promyelocytic Leukemia
Enrollment Status: Recruiting
Publish Date: December 17, 2025
Intervention Type: Drug, Other
Study Drugs: Arsenic Trioxide, Gemtuzumab, Tretinoin
Study Phase: Phase 2

Summary: This phase II trial studies how well tretinoin and arsenic trioxide with or without gemtuzumab ozogamicin works in treating patients with previously untreated acute promyelocytic leukemia. Drugs used in chemotherapy, such as tretinoin and arsenic trioxide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them fro...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center